Publications by authors named "Junya Imaizumi"
Article Synopsis
- This study is a follow-up on the effectiveness and safety of tazemetostat for Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) who have the EZH2 mutation, after a median follow-up of 35 months.
- The FL cohort had an impressive objective response rate of 70.6%, with significant progression-free survival (PFS) rates at 24 and 36 months (72.1% and 64.1% respectively), while no unexpected severe adverse events were reported.
- Overall, long-term treatment with tazemetostat appears to be a promising and safe option as a third-line or later therapy for patients with this specific
The efficiency of upfront consolidation with high-dose chemotherapy/autologous stem-cell transplantation (HDCT/ASCT) for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in high-risk DLBCL patients having an age-adjusted International Prognostic Index (aaIPI) score of 2 or 3. As induction chemotherapy, 6 cycles of R-CHOP-14 (arm A) or 3 cycles of R-CHOP-14 followed by 3 cycles of CHASER (arm B) were planned, and patients who responded proceeded to HDCT with LEED and ASCT.
View Article and Find Full Text PDFAim: To clarify the significance of combined resection of the spleen to dissect the No. 10 lymph node (LN).
Methods: We studied 191 patients who had undergone total gastrectomy with splenectomy, excluding non-curative cases, resection of multiple gastric cancer, and those with remnant stomach cancer.